Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
This page provides an archive of news coverage for ESSA Pharma Inc. (former NASDAQ: EPIX), a pharmaceutical company that was previously focused on developing novel and proprietary therapies for patients with prostate cancer. The news items collected here document ESSA’s transition from a clinical-stage oncology-focused issuer to a company that discontinued and wound up its business in connection with an acquisition by XenoTherapeutics Inc.
According to ESSA’s press releases, the company entered into a Business Combination Agreement with XenoTherapeutics, a Massachusetts-based non-profit biotechnology organization, under which a wholly owned Xeno subsidiary acquired all of the issued and outstanding ESSA common shares. The news flow tracks key milestones in this process, including the announcement of the definitive agreement, applications to the Supreme Court of British Columbia for interim and distribution orders, and the scheduling and adjournment of special meetings of shareholders, optionholders and warrantholders.
Readers can review announcements related to ESSA’s US$80 million return of capital distribution, Nasdaq’s due bill trading mechanics for that distribution, subsequent clarifications about the due bill period, and updates on revised financial terms of the transaction. Later releases describe securityholder approval of the arrangement, court approval, and the closing of the acquisition, as well as ESSA’s request for delisting from Nasdaq.
For investors and researchers, this news archive offers detailed historical context on how ESSA managed its corporate transaction, cash distributions, and governance approvals leading up to its acquisition and delisting. It is useful for understanding the sequence of events that affected holders of EPIX shares and for examining how a publicly traded pharmaceutical issuer executed a court-supervised plan of arrangement and winding-up process.
ESSA Pharma Inc. (Nasdaq: EPIX) announced the first patient has been dosed in a Phase 1 clinical trial for EPI-7386, targeting metastatic castration-resistant prostate cancer (mCRPC) patients who have failed standard treatments. This small molecule inhibitor aims to demonstrate safety and tolerability while exploring its pharmacokinetic and anti-tumor effects. Approximately 18 patients will participate in the dose escalation phase, with further expansion expected. CEO David Parkinson highlighted this milestone as a step towards offering new treatment options for mCRPC patients.
ESSA Pharma Inc. (Nasdaq: EPIX) presented promising preclinical data on its drug candidate EPI-7386 at the 2020 AACR Virtual Annual Meeting II. The data confirm full-length androgen receptor (AR) engagement and demonstrate EPI-7386's ability to inhibit AR activity effectively, showing superior results over enzalutamide in certain models. Toxicology studies indicate a favorable safety profile, with the starting clinical dose set at 200 mg daily. ESSA plans to initiate a Phase 1 study targeting patients with castration-resistant prostate cancer, addressing a critical unmet need in cancer treatment.